PubMed Health⌕ Search

Biomedical subjects

U Budimulja

Publications and source records attributed to U Budimulja.

6 recordsLinked to original sources
PubMed2001

Once daily treatment with terbinafine 1% cream (Lamisil) for one week is effective in the treatment of tinea corporis and cruris. A placebo-controlled study.

Duration of therapy is an important factor in determining patients' compliance in dermatomycosis. Terbinafine (Lamisil) is an allylamine antifungal agent. Its fungicidal properties against dermatophytes should allow physicians to reduce treatment duration without affecting the cure rate. This study was carried out to determine the efficacy and tolerability of terbinafine 1% cream, applied once daily for 7 days, in adult patients with tinea corporis/cruris. In a multicentre, randomized, double-blind, parallel-group study, patients with a clinical diagnosis of tinea corporis/cruris confirmed by microscopy and culture received treatment with either terbinafine 1% cream (n = 57) or placebo cream (n = 60). The patients applied the cream once daily for 7 days, and were then observed for a further 7 weeks. The efficacy was assessed at the end of the study by comparing the rates of mycological cure in the two treatment groups. Total clinical signs and symptoms scores, clinical response, and overall treatment efficacy were also measured and compared between the two groups. A 7-day once-daily course of terbinafine was significantly more effective than placebo in achieving and maintaining mycological cure (84.2 versus 23.3%, P< 0.001). Terbinafine was also significantly more effective than placebo in terms of clinical response, reduction in signs and symptoms scores, and overall efficacy. The short treatment regimen and the sustained high cure rate should contribute to making terbinafine a valuable treatment option in tinea corporis/cruris.

Administration, Cutaneous↗
PubMed1994

A double-blind, randomized, stratified controlled study of the treatment of tinea imbricata with oral terbinafine or itraconazole.

This study compared the efficacy of the new fungicidal allylamine antimycotic, terbinafine, with the triazole antimycotic, itraconazole, in patients with chronic tinea imbricata. Forty-three patients received terbinafine 250 mg daily, and 40 received itraconazole 100 mg daily, for 4 weeks. A total of 72 patients were eligible for follow-up at weeks 5 and 17. Of these, four patients, all from the itraconazole group, did not respond either clinically or mycologically. All of the remaining 68 patients were clinically and mycologically cured. No adverse effects were reported in either group. Terbinafine was assessed as having a superior clinical and mycological cure rate to itraconazole after 4 weeks (P = 0.05) with borderline statistical significance. In addition, after 13 weeks of follow-up, terbinafine provided a significantly reduced rate of reinfection/relapse from further T. concentricum infection compared with itraconazole (P < 0.001). This superior protective effect may be explained by the fungicidal activity and the long persistance in the skin of terbinafine, and indicates the need for higher doses of itraconazole in this particular infection.

Administration, Oral↗